Litcius/Paper detail

Updated Efficacy and Safety Data from IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma

Akash Roy

2022Journal of Clinical and Experimental Hepatology37 citationsDOIOpen Access PDF

Topics & Concepts

AtezolizumabMedicineSorafenibBevacizumabHepatocellular carcinomaOncologyInternal medicineCancerChemotherapyImmunotherapyPembrolizumabHepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and TreatmentHepatitis B Virus Studies
Updated Efficacy and Safety Data from IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma | Litcius